Literature DB >> 6128713

Metabolism and excretion of the quaternary ammonium compound thiazinamium methylsulfate (Multergan) in man. I. Parenteral administration.

J H Jonkman, J Wijsbeek, R A De Zeeuw, L E Van Bork, N G Orie, A M Soeterboek, J Bender.   

Abstract

The quaternary ammonium compound thiazinamium was found to be metabolized by sulfoxidation solely. No ring hydroxylation products, nor demethylation products (e.g. promethazine) could be found. Thiazinamium sulfoxide was found both in urine and bile, but thiazinamium is-after parenteral administration - mainly excreted in the unchanged form. After intravenous injection about 40% of the dose was excreted, unchanged, in the urine. The excretion was very rapid and almost complete within eight hours. About 9% of the dose was excreted in the urine in the form of thiazinamium sulfoxide cations. After intramuscular injection virtually the same figures for urinary excretion were found. No correlation could be observed between urine production or pH and the amount of drug excreted in urine. In a study involving bile-fistula patients it was found that both thiazinamium cations and thiazinamium sulfoxide cations are excreted to a considerable extent in bile. The amount of unchanged drug in bile was almost equal to that in urine, but the amount of sulfoxide was slightly higher.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128713     DOI: 10.1007/bf01959029

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  11 in total

1.  Determination of thiazinamium sulphoxide in urine by means of amberlite XAD-2 column chromatography and thin-layer densitometry.

Authors:  J H Jonkman; J Wijsbeek; J E Greving; R E Van Gorp; R A De Zeeuw
Journal:  J Chromatogr       Date:  1976-11-17

2.  [Diagnostic and therapeutic use of thiazinamium (Multergan)].

Authors:  L E van Bork; J H Jonkman; R A de Zeeuw; N G Orie; R Peset; K de Vries
Journal:  Ned Tijdschr Geneeskd       Date:  1977-07-23

3.  Determination of low cencentrations of the quaternary ammonium compound thiazinamium methylsulphate in plasma and urine.

Authors:  J G Jonkman; J Wijsbeek; S Hollenbeek; S H de Boer; R A de Zeeuw; L E Van Bork; N G Orie
Journal:  J Pharm Pharmacol       Date:  1975-11       Impact factor: 3.765

Review 4.  [Treatment of CARA].

Authors:  H J Sluiter; K de Vries
Journal:  Ned Tijdschr Geneeskd       Date:  1974-07-13

5.  Gas chromatographic identification of thioridazine in plasma, and a method for routine assay of the drug.

Authors:  S H Curry; G P Mould
Journal:  J Pharm Pharmacol       Date:  1969-10       Impact factor: 3.765

6.  Protection tests on bronchial allergen challenge with disodium cromoglycate and thiazinamium.

Authors:  H Booij-Noord; N G Orie; W C Berg; K de Vries
Journal:  J Allergy       Date:  1970-07

7.  Fate of emepronium in man in relation to its pharmacological effects.

Authors:  A Sundwall; J Vessman; B Strindberg
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

8.  Distribution, excretion, and metabolism of 14C-labeled quaternary ammonium salt of mepazine and promethazine in rats.

Authors:  C L Huang; J A Yeh; S Y Hsu
Journal:  J Pharm Sci       Date:  1970-06       Impact factor: 3.534

9.  Metabolic disposition of emepronium in the dog with a note on the relationship between plasma concentration and effect.

Authors:  A Sundwall; K Uthne; J Vessman
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

10.  Hepatic disposition and biliary excretion of the organic cations thiazinamium and thiazinamium sulfoxide in rats.

Authors:  K Neef; J H Jonkman; D K Meijer
Journal:  J Pharm Sci       Date:  1978-08       Impact factor: 3.534

View more
  1 in total

1.  Metabolism and excretion of the quaternary ammonium compound thiazinamium methylsulfate (Multergan) in man. II. Oral and rectal administration.

Authors:  J H Jonkman; J Wijsbeek; R A De Zeeuw; L E Van Bork; N G Orie
Journal:  Pharm Weekbl Sci       Date:  1982-10-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.